Recent advances in antileukotriene therapy

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 4, 2010, Pages 370-376

  Scadding, Guy W ^a   Scadding, Glenis K ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Royal National TNE Hospital   (United Kingdom)

Author keywords

antileukotriene; asthma; LTE4; pharmacogenetics; rhinitis

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FEXOFENADINE; FLUTICASONE; FLUTICASONE PROPIONATE; LEUKOTRIENE A4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MONTELUKAST; PLACEBO; SALBUTAMOL; ZILEUTON; ANTIASTHMATIC AGENT;

ADD ON THERAPY; ALLERGIC RHINITIS; ASTHMA; BRONCHIOLITIS; CHRONIC URTICARIA; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENVIRONMENTAL FACTOR; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HAY FEVER; HUMAN; LIVER TOXICITY; NONHUMAN; NOSE POLYP; PATIENT COMPLIANCE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RHINOSINUSITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDERED BREATHING; TREATMENT RESPONSE; URTICARIA; WHEEZING; ADOLESCENT; ADULT; ANIMAL; CHILD; CLINICAL TRIAL (TOPIC); GUINEA PIG; METABOLISM; MOUSE; PRESCHOOL CHILD; RHINITIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; GUINEA PIGS; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE E4; MICE; RHINITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954661390     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32833bfa20     Document Type: Review

References (56)

1. Murphy RC, Hammarstrom S, Samuelsson B, Leukotriene C. A slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A 1979; 76:4275-4279.
2. Morris HR, Taylor GW, Piper PJ, Tippins JR. Structure of slow-reacting substance of anaphylaxis from guinea-pig lung. Nature 1980; 285:104-106.
3. Duroudier NP, Tulah AS, Sayers I. Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy 2009; 64:823-839.
4. Tantisira KG, Drazen JM. Genetics and pharmacogenetics of the leukotriene pathway. J Allergy Clin Immunol 2009; 124:422-427.
5. Duroudier NP, Strachan DP, Blakey JD, Hall IP. Association of the cysteinyl leukotriene receptor 1 gene with atopy in the British 1958 birth cohort. J Allergy Clin Immunol 2009; 124:566-572.
6. Via M, De Giacomo A, Corvol H, et al. The role of LTA4H and ALOX5AP genes in the risk for asthma in Latinos. Clin Exp Allergy 2010 [Epub ahead of print].
7. Holloway JW, Barton SJ, Holgate ST, et al. The role of LTA4H and ALOX5AP polymorphism in asthma and allergy susceptibility. Allergy 2008; 63:1046-1053.
8. Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009; 19: 129-138.
9. Austen KF, Maekawa A, Kanaoka Y, Boyce JA. The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol 2009; 124:406-414.
10. Lee TH, Woszczek G, Farooque SP. Leukotriene E4: perspective on the forgotten mediator. J Allergy Clin Immunol 2009; 124:417-421.
11. Maekawa A, Kanaoka Y, Xing W, Austen KF. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 2008; 105:16695-16700.
12. Paruchuri S, Tashimo H, Feng C, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 2009; 206:2543-2555.
13. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-178.
14. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and nonallergic rhinitis. Clin Exp Allergy 2008; 38: 19-42.
15. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427-1443.
16. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233-242.
17. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130:487-495.
18. Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002; 110:847-854.
19. Rabinovitch N, Strand M, Stuhlman K, Gelfand EW. Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J Allergy Clin Immunol 2008; 121:1365-1371.
20. Langmack EL, Martin RJ. Heterogeneity of response to asthma controller therapy: clinical implications. Curr Opin Pulm Med 2010; 16:13-18.
21. Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117:45-52.
22. Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175:783-790.
23. Telleria JJ, Blanco-Quiros A, Varillas D, et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med 2008; 102:857-861.
24. Lima JJ, Blake KV, Tantisira KG, Weiss ST. Pharmacogenetics of asthma. Curr Opin Pulm Med 2009; 15:57-62.
25. Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007; 17:189-196.
26. Kim SH, Hur GY, Choi JH, Park HS. Pharmacogenetics of aspirin-intolerant asthma. Pharmacogenomics 2008; 9:85-91.
27. Kang MJ, Lee SY, Kim HB, et al. Association of IL-13 polymorphisms with leukotriene receptor antagonist drug responsiveness in Korean children with exercise-induced bronchoconstriction. Pharmacogenet Genomics 2008; 18:551-558.
28. Taegtmeyer AB, Steurer-Stey C, Price DB, et al. Predictors of asthma control in everyday clinical practice in Switzerland. Curr Med Res Opin 2009; 25:2549-2555.
29. Virchow JC, Mehta A, Ljungblad L, et al. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic asthma (MONICA) study. Respir Med 2010; 104 (5):644-651.
30. Zubairi ABS, Haque AS, Waheed S, et al. A randomized, double-blinded, placebo-controlled clinical trial of oral montelukast in acute asthma exacerbation (PTOMA trial). Respirology 2008; 13(Suppl 5):A131 (#018-01).
31. Ramsay C, Pearson D, Wilson A. Oral montelukast in patients with acute severe asthma. Eur Respir J 2007; 30(Suppl 51):#P3609.
32. Smithline H, Camargo C Jr, Gurner D, et al. Intravenous montelukast as an adjunctive treatment of acute asthma. Acad Emerg Med 2008; 15(Suppl 1): S14 (#20).
33. Hay J, Jhaveri M, Tangirala M, Kaliner M. Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. Allergy Asthma Proc 2009; 30:634-642.
34. Lu S, Malice MP, Dass SB, Reiss TF. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis. J Asthma 2009; 46:878-883.
35. Di Capite J, Nelson C, Bates G, Parekh AB. Targeting Ca2+ release-activated Ca2+ channel channels and leukotriene receptors provides a novel combination strategy for treating nasal polyposis. J Allergy Clin Immunol 2009; 124:1014-1210.
36. Bacharier LB, Phillips BR, Zeiger RS, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children withmoderate-tosevere intermittent wheezing. J Allergy Clin Immunol 2008; 122:1127-1135.
37. Bisgaard H, Flores-Nunez A, Goh A, et al. Study of montelukast for the treatment of respiratory symptoms of postrespiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 2008; 178:854-860.
38. Amirav I, Luder AS, Kruger N, et al. A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics 2008; 122:e1249-e1255.
39. Bisgaard H, Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus post bronchiolitis. Am J Respir Crit Care Med 2003; 167:379-383.
40. Knuffman JE, Sorkness CA, Lemanske RF Jr, et al. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. J Allergy Clin Immunol 2009; 123:411-416.
41. Tcheurekdjian H, Thyne SM, Williams LK, et al. Augmentation of bronchodilator responsiveness by leukotriene modifiers in Puerto Rican and Mexican children. Ann Allergy Asthma Immunol 2009; 102:510-517.
42. Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362 (11):975-985.
43. Schuh S, Willan AR, Stephens D, et al. Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial. J Pediatr 2009; 155:795-800.
44. Strunk RC, Bacharier LB, Phillips BR, et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol 2008; 122:1138-1144.
45. Bukstein DA, Bratton DL, Firriolo KM, et al. Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. J Asthma 2003; 40:475-485.
46. McNally KA, Rohan J, Schluchter M, et al. Adherence to combined montelukast and fluticasone treatment in economically disadvantaged African American youth with asthma. J Asthma 2009; 46:921-927.
47. Li AM, Abdullah VJ, Tsen CS, et al. Leukotriene receptor antagonist in the treatment of childhood allergic rhinitis: a randomized placebo-controlled study. Pediatr Pulmonol 2009; 44:1085-1092.
48. Goldbart AD, Goldman JL, Veling MC, Gozal D. Leukotriene modifier therapy for mild sleep-disordered breathing in children. Am J Respir Crit Care Med 2005; 172:364-370.
49. Dayyat E, Serpero LD, Kheirandish-Gozal L, et al. Leukotriene pathways and in vitro adenotonsillar cell proliferation in children with obstructive sleep apnea. Chest 2009; 135:1142-1149.
50. Kaditis AG, Alexopoulos E, Chaidas K, et al. Urine concentrations of cysteinyl leukotrienes in children with obstructive sleep-disordered breathing. Chest 2009; 135:1496-1501.
51. Friesen CA, Neilan NA, Schurman JV, et al. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol 2009; 9:32.
52. Philip G, Hustad CM, Malice MP, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009; 124:699-706.
53. Philip G, Hustad C, Noonan G, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009; 124:691-696.
54. Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009; 44:568-579.
55. Bibby S, Healy B, Steele R, et al. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax 2010; 65:132-138.
56. Joshi EM, Heasley BH, Macdonald TL. 2-ABT-S-oxide detoxification by glutathione S-transferases A1-1, M1-1 and P1-1: implications for toxicity associated with zileuton. Xenobiotica 2009; 39:197-204.